Ondine Biomedical Inc

LSE:OBI UK Biotechnology
Market Cap
$678.01K
GBX5.57 Billion GBX
Market Cap Rank
#45773 Global
#899 in UK
Share Price
GBX10.75
Change (1 day)
-2.27%
52-Week Range
GBX8.00 - GBX18.00
All Time High
GBX58.50
Categories
Companies in UK Biotechnology
About

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more

Ondine Biomedical Inc (OBI) - Net Assets

Latest net assets as of December 2024: GBX6.88 Million GBX

Based on the latest financial reports, Ondine Biomedical Inc (OBI) has net assets worth GBX6.88 Million GBX as of December 2024.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX12.82 Million) and total liabilities (GBX5.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX6.88 Million
% of Total Assets 53.63%
Annual Growth Rate 7.08%
5-Year Change N/A
10-Year Change 438.17%
Growth Volatility 731.83

Ondine Biomedical Inc - Net Assets Trend (2001–2024)

This chart illustrates how Ondine Biomedical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Ondine Biomedical Inc (2001–2024)

The table below shows the annual net assets of Ondine Biomedical Inc from 2001 to 2024.

Year Net Assets Change
2024-12-31 GBX6.88 Million +229.83%
2023-12-31 GBX2.08 Million -82.09%
2022-12-31 GBX11.64 Million -60.74%
2021-12-31 GBX29.66 Million +187.67%
2020-12-31 GBX-33.83 Million -29.74%
2019-12-31 GBX-26.07 Million -45.68%
2018-12-31 GBX-17.90 Million -173.34%
2017-12-31 GBX-6.55 Million -2445.38%
2010-12-31 GBX279.19K -78.15%
2009-12-31 GBX1.28 Million -4.44%
2008-12-31 GBX1.34 Million -87.67%
2007-12-31 GBX10.84 Million -34.64%
2006-12-31 GBX16.59 Million +0.53%
2005-12-31 GBX16.50 Million +7350.48%
2003-08-31 GBX-227.62K -58.87%
2002-08-31 GBX-143.28K -110.28%
2001-08-31 GBX1.39 Million --

Equity Component Analysis

This analysis shows how different components contribute to Ondine Biomedical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 28480831100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock GBX262.60 Million 3818.51%
Other Components GBX29.71 Million 432.02%
Total Equity GBX6.88 Million 100.00%

Ondine Biomedical Inc Competitors by Market Cap

The table below lists competitors of Ondine Biomedical Inc ranked by their market capitalization.

Company Market Cap
Alexandria Containers and goods
EGX:ALCN
 		$5.93K
CHINA SOUTHN AIR-H-
BE:ZNHH
 		$5.94K
HBSA3F
SA:HBSA3F
 		$5.94K
China Networks International Holdings Ltd
PINK:CNWHF
 		$5.94K
SHS
VN:SHS
 		$5.93K
ASHANTE GOLD CORPORATION
GSE:ASG
 		$5.92K
SIETEL 5% CUM PF
AU:SSLPA
 		$5.92K
SDM SE INH O.N.
F:75S
 		$5.92K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ondine Biomedical Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,085,000 to 6,877,000, a change of 4,792,000 (229.8%).
  • Net loss of 19,098,000 reduced equity.
  • New share issuances of 22,980,000 increased equity.
  • Other factors increased equity by 910,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX-19.10 Million -277.71%
Share Issuances GBX22.98 Million +334.16%
Other Changes GBX910.00K +13.23%
Total Change GBX- 229.83%

Book Value vs Market Value Analysis

This analysis compares Ondine Biomedical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 429.25x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 10.45x to 429.25x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-08-31 GBX1.03 GBX10.75 x
2002-08-31 GBX-0.11 GBX10.75 x
2003-08-31 GBX-0.17 GBX10.75 x
2005-12-31 GBX0.41 GBX10.75 x
2006-12-31 GBX0.35 GBX10.75 x
2007-12-31 GBX0.20 GBX10.75 x
2008-12-31 GBX0.02 GBX10.75 x
2009-12-31 GBX0.01 GBX10.75 x
2010-12-31 GBX0.00 GBX10.75 x
2017-12-31 GBX-0.03 GBX10.75 x
2018-12-31 GBX-0.09 GBX10.75 x
2019-12-31 GBX-0.13 GBX10.75 x
2020-12-31 GBX-0.17 GBX10.75 x
2021-12-31 GBX0.15 GBX10.75 x
2022-12-31 GBX0.06 GBX10.75 x
2023-12-31 GBX0.01 GBX10.75 x
2024-12-31 GBX0.03 GBX10.75 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ondine Biomedical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -277.71%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -932.06%
  • • Asset Turnover: 0.16x
  • • Equity Multiplier: 1.86x
  • Recent ROE (-277.71%) is below the historical average (-226.40%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -5.26% 0.00% 0.00x 1.04x GBX-212.71K
2002 0.00% 0.00% 0.00x 0.00x GBX-1.52 Million
2003 0.00% 0.00% 0.00x 0.00x GBX-61.58K
2005 -51.74% 0.00% 0.00x 1.05x GBX-10.19 Million
2006 -72.10% -738.91% 0.09x 1.11x GBX-13.62 Million
2007 -121.30% -819.56% 0.12x 1.20x GBX-14.24 Million
2008 -767.99% -1125.69% 0.31x 2.20x GBX-10.40 Million
2009 -359.59% -446.12% 0.39x 2.05x GBX-4.72 Million
2010 -1166.60% -212.46% 0.60x 9.08x GBX-3.28 Million
2017 0.00% -1561.65% 0.07x 0.00x GBX-5.78 Million
2018 0.00% -4465.42% 0.08x 0.00x GBX-14.87 Million
2019 0.00% -3014.01% 0.16x 0.00x GBX-11.38 Million
2020 0.00% -908.49% 0.68x 0.00x GBX-12.89 Million
2021 -168.88% -1949.59% 0.08x 1.15x GBX-53.05 Million
2022 -166.37% -3036.36% 0.04x 1.42x GBX-20.54 Million
2023 -691.22% -1198.00% 0.21x 2.75x GBX-14.62 Million
2024 -277.71% -932.06% 0.16x 1.86x GBX-19.79 Million

Industry Comparison

This section compares Ondine Biomedical Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $16,922,054
  • Average return on equity (ROE) among peers: -43.36%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Ondine Biomedical Inc (OBI) GBX6.88 Million -5.26% 0.86x $5.93K
4BASEBIO UK SOCIETAS (4BB) $-1.89 Million 0.00% 0.00x $10.53K
Aptamer Group PLC (APTA) $887.00K -333.48% 2.12x $3.12K
Arecor Therapeutics PLC (AREC) $17.45 Million -53.05% 0.25x $3.33K
Bioventix (BVXP) $2.37 Million 0.00% 0.08x $9.85K
Cizzle Biotechnology Holdings PLC (CIZ) $4.27 Million -15.25% 0.73x $747.56
Fusion Antibodies PLC (FAB) $655.00K 0.00% 0.71x $2.07K
Faron Pharmaceuticals Oy (FARN) $-1.19 Million 0.00% 0.00x $27.00K
Futura Medical (FUM) $8.85 Million -66.43% 0.23x $424.60
hVIVO plc (HVO) $8.89 Million 5.10% 0.41x $5.18K
International Biotechnology Trust plc (IBT) $128.92 Million 29.48% 0.00x $1.05K